Skip to main content
. 2021 Mar 22;21(5):406. doi: 10.3892/ol.2021.12667

Figure 2.

Figure 2.

ADCC activity against RLUN021. (A) Cetuximab and (B) bevacizumab. The vertical axis indicates the emission value. The activity was measured 5 h after the addition of the effector cells. The data are presented as the mean ± SD of three replicate samples. *P<0.05 vs. each group without antibody (A, RLUN021 with ADCC Bioassay Effector Cell or ADCC Bioassay Effector Cell without cetuximab; B, RLUN021 with ADCC Bioassay Effector Cell or ADCC Bioassay Effector Cell without bevacizumab), calculated by Dunnett's test after one-way ANOVA. ns, not significant; ADCC, antibody-dependent cellular cytotoxicity.